Top

Published in:

01-11-2018 | Original Communication

Platelet-derived extracellular vesicles in Huntington’s disease

Authors: Hélèna L. Denis, Jérôme Lamontagne-Proulx, Isabelle St-Amour, Sarah L. Mason, Andreas Weiss, Sylvain Chouinard, Roger A. Barker, Eric Boilard, Francesca Cicchetti

Published in: Journal of Neurology | Issue 11/2018

Abstract

The production and release of extracellular vesicles (EV) is a property shared by all eukaryotic cells and a phenomenon frequently exacerbated in pathological conditions. The protein cargo of EV, their cell type signature and availability in bodily fluids make them particularly appealing as biomarkers. We recently demonstrated that platelets, among all types of blood cells, contain the highest concentrations of the mutant huntingtin protein (mHtt)—the genetic product of Huntington’s disease (HD), a neurodegenerative disorder which manifests in adulthood with a complex combination of motor, cognitive and psychiatric deficits. Herein, we used a cohort of 59 HD patients at all stages of the disease, including individuals in pre-manifest stages, and 54 healthy age- and sex-matched controls, to evaluate the potential of EV derived from platelets as a biomarker. We found that platelets of pre-manifest and manifest HD patients do not release more EV even if they are activated. Importantly, mHtt was not found within EV derived from platelets, despite them containing high levels of this protein. Correlation analyses also failed to reveal an association between the number of platelet-derived EV and the age of the patients, the number of CAG repeats, the Unified Huntington Disease Rating Scale total motor score, the Total Functional Capacity score or the Burden of Disease score. Our data would, therefore, suggest that EV derived from platelets with HD is not a valuable biomarker in HD.

Available only for authorised users

Manyam BV, Katz L, Hare TA et al (1981) Isoniazid-induced elevation of CSF GABA levels and effects on chorea in Huntington’s disease. Ann Neurol 10:35–37. https://doi.org/10.1002/ana.410100107 CrossRefPubMed

Manyam NV, Hare TA, Katz L (1980) Effect of isoniazid on cerebrospinal fluid and plasma GABA levels in Huntington’s disease. Life Sci 26:1303–1308. https://doi.org/10.1016/0024-3205(80)90089-2 CrossRefPubMed

Silajdzic E, Rezeli M, Vegvari A et al (2013) A critical evaluation of inflammatory markers in Huntington’s disease plasma. J Huntingt Dis 2:125–134. https://doi.org/10.3233/jhd-130049 CrossRef

Björkqvist M, Wild EJ, Thiele J et al (2008) A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington’s disease. J Exp Med 205:1869–1877. https://doi.org/10.1084/jem.20080178 CrossRefPubMedPubMedCentral

Aronson NN, Blanchard CJ, Madura JD (1997) Homology modeling of glycosyl hydrolase family 18 enzymes and proteins. J Chem Inf Comput Sci 37:999–1005. https://doi.org/10.1021/ci970236v CrossRefPubMed

Vinther-Jensen T, Budtz-Jorgensen E, Simonsen AH et al (2014) YKL-40 in cerebrospinal fluid in Huntington’s disease—a role in pathology or a nonspecific response to inflammation? Parkinsonism Relat Disord 20:1301–1303. https://doi.org/10.1016/j.parkreldis.2014.08.011 CrossRefPubMed

Georgiou-Karistianis N, Scahill R, Tabrizi SJ et al (2013) Structural MRI in Huntington’s disease and recommendations for its potential use in clinical trials. Neurosci Biobehav Rev 37:480–490. https://doi.org/10.1016/j.neubiorev.2013.01.022 CrossRefPubMed

Sanchez-Castaneda C, Cherubini A, Elifani F et al (2013) Seeking Huntington disease biomarkers by multimodal, cross-sectional basal ganglia imaging. Hum Brain Mapp 34:1625–1635. https://doi.org/10.1002/hbm.22019 CrossRefPubMed

Bialas WA, Markesbery WR, Butterfield DA (1980) Increased chloride transport in erythrocytes in Huntington’s disease. Biochem Biophys Res Commun 95:1895–1900. https://doi.org/10.1016/S0006-291X(80)80121-5 CrossRefPubMed

10.

Chen C-M, Wu Y-R, Cheng M-L et al (2007) Increased oxidative damage and mitochondrial abnormalities in the peripheral blood of Huntington’s disease patients. Biochem Biophys Res Commun 359:335–340. https://doi.org/10.1016/j.bbrc.2007.05.093 CrossRefPubMed

11.

Kraus PH, Vigenschow H, Przuntek H (1986) Spin label study of red blood cell membranes in Huntington’s disease. Eur Neurol 25:61–66. https://doi.org/10.1159/000115988 CrossRefPubMed

12.

Zakharov SF, Shandala AM, Shcheglova MV et al (1990) Comparative study of human erythrocyte membranes in normal people and in Huntington’s chorea patients. Vopr Med Khim 36:71–73PubMed

13.

Andre R, Carty L, Tabrizi SJ (2016) Disruption of immune cell function by mutant huntingtin in Huntington’s disease pathogenesis. Curr Opin Pharmacol 26:33–38. https://doi.org/10.1016/j.coph.2015.09.008 CrossRefPubMed

14.

Cheng M-L, Chang K-H, Wu Y-R, Chen C-M (2016) Metabolic disturbances in plasma as biomarkers for Huntington’s disease. J Nutr Biochem 31:38–44. https://doi.org/10.1016/j.jnutbio.2015.12.001 CrossRefPubMed

15.

Narayanan KL, Chopra V, Rosas HD et al (2016) Rho kinase pathway alterations in the brain and leukocytes in Huntington’s disease. Mol Neurobiol 53:2132–2140. https://doi.org/10.1007/s12035-015-9147-9 CrossRefPubMed

16.

Träger U, Andre R, Lahiri N et al (2014) HTT-lowering reverses Huntington’s disease immune dysfunction caused by NFκB pathway dysregulation. Brain 137:819–833. https://doi.org/10.1093/brain/awt355 CrossRefPubMedPubMedCentral

17.

Varani K, Abbracchio MP, Cannella M et al (2003) Aberrant A2A receptor function in peripheral blood cells in Huntington’s disease. FASEB J 17:2148–2150. https://doi.org/10.1096/fj.03-0079fje CrossRefPubMed

18.

Weiss A, Trager U, Wild EJ et al (2012) Mutant huntingtin fragmentation in immune cells tracks Huntington’s disease progression. J Clin Investig 122:3731–3736. https://doi.org/10.1172/jci64565 CrossRefPubMedPubMedCentral

19.

Aminoff MJ, Trenchard A, Turner P et al (1974) Plasma uptake of dopamine and 5-hydroxytryptamine and plasma-catecholamine levels in patients with Huntington’s chorea. Lancet 2:1115–1116. https://doi.org/10.1016/S0140-6736(74)90873-3 CrossRefPubMed

20.

Diez-Ewald M, Bonilla E, Gonzalez JV (1980) Platelet aggregation, 5-hydroxytryptamine uptake and release in Huntington’s chorea. Prog Neuropsychopharmacol Biol Psychiatry 4:277–283CrossRef

21.

Gu M, Gash MT, Mann VM et al (1996) Mitochondrial defect in Huntington’s disease caudate nucleus. Ann Neurol 39:385–389. https://doi.org/10.1002/ana.410390317 CrossRefPubMed

22.

Maglione V, Cannella M, Martino T et al (2006) The platelet maximum number of A2A-receptor binding sites (Bmax) linearly correlates with age at onset and CAG repeat expansion in Huntington’s disease patients with predominant chorea. Neurosci Lett 393:27–30. https://doi.org/10.1016/j.neulet.2005.09.037 CrossRefPubMed

23.

Markianos M, Panas M, Kalfakis N, Vassilopoulos D (2004) Platelet monoamine oxidase activity in subjects tested for Huntington’s disease gene mutation. J Neural Transm 111:475–483. https://doi.org/10.1007/s00702-003-0103-x CrossRefPubMed

24.

Muramatsu Y, Kaiya H, Imai H et al (1982) Abnormal platelet aggregation response in Huntington’s disease. Arch Psychiatry Neurol Sci (1970) 232:191–200. https://doi.org/10.1007/BF02141780 CrossRef

25.

Reilmann R, Rolf LH, Lange HW (1994) Huntington’s disease: the neuroexcitotoxin aspartate is increased in platelets and decreased in plasma. J Neurol Sci 127:48–53. https://doi.org/10.1016/0022-510X(94)90134-1 CrossRefPubMed

26.

Silva AC, Almeida S, Laço M et al (2013) Mitochondrial respiratory chain complex activity and bioenergetic alterations in human platelets derived from pre-symptomatic and symptomatic Huntington’s disease carriers. Mitochondrion 13:801–809. https://doi.org/10.1016/j.mito.2013.05.006 CrossRefPubMed

27.

Tukiainen E, Wikström J, Kilpeläinen H (1981) Uptake of 5-hydroxytryptamine by blood platelets in Huntington’s chorea and Alzheimer type of presenile dementia. Med Biol 59:116–120PubMed

28.

Leoni V, Caccia C (2015) The impairment of cholesterol metabolism in Huntington disease. Biochem Biophys Acta 1851:1095–1105. https://doi.org/10.1016/j.bbalip.2014.12.018 CrossRefPubMed

29.

Weiss A, Abramowski D, Bibel M et al (2009) Single-step detection of mutant huntingtin in animal and human tissues: a bioassay for Huntington’s disease. Anal Biochem 395:8–15. https://doi.org/10.1016/j.ab.2009.08.001 CrossRefPubMed

30.

Anderson AN, Roncaroli F, Hodges A et al (2008) Chromosomal profiles of gene expression in Huntington’s disease. Brain 131:381–388. https://doi.org/10.1093/brain/awm312 CrossRefPubMed

31.

Borovecki F, Lovrecic L, Zhou J et al (2005) Genome-wide expression profiling of human blood reveals biomarkers for Huntington’s disease. Proc Natl Acad Sci 102:11023–11028. https://doi.org/10.1073/pnas.0504921102 CrossRefPubMedPubMedCentral

32.

Aylward EH, Nopoulos PC, Ross CA et al (2011) Longitudinal change in regional brain volumes in prodromal Huntington disease. J Neurol Neurosurg Psychiatry 82:405–410. https://doi.org/10.1136/jnnp.2010.208264 CrossRefPubMed

33.

Bohanna I, Georgiou-Karistianis N, Sritharan A et al (2011) Diffusion tensor imaging in Huntington’s disease reveals distinct patterns of white matter degeneration associated with motor and cognitive deficits. Brain Imaging Behav 5:171–180. https://doi.org/10.1007/s11682-011-9121-8 CrossRefPubMed

34.

Davie CA, Barker GJ, Quinn N et al (1994) Proton MRS in Huntington’s disease. Lancet 343:1580. https://doi.org/10.1016/S0140-6736(94)92987-4 CrossRefPubMed

35.

Jenkins BG, Rosas HD, Chen YC et al (1998) 1H NMR spectroscopy studies of Huntington’s disease: correlations with CAG repeat numbers. Neurology 50:1357–1365CrossRefPubMed

36.

Paulsen JS, Zimbelman JL, Hinton SC et al (2004) fMRI biomarker of early neuronal dysfunction in presymptomatic Huntington’s disease. Am J Neuroradiol 25:1715–1721PubMedPubMedCentral

37.

Rosas HD, Chen YI, Doros G et al (2012) Alterations in brain transition metals in Huntington disease: an evolving and intricate story. Arch Neurol 69:887–893. https://doi.org/10.1001/archneurol.2011.2945 CrossRefPubMedPubMedCentral

38.

Ruocco HH, Bonilha L, Li LM et al (2008) Longitudinal analysis of regional grey matter loss in Huntington disease: effects of the length of the expanded CAG repeat. J Neurol Neurosurg Psychiatry 79:130–135. https://doi.org/10.1136/jnnp.2007.116244 CrossRefPubMed

39.

Shin H, Kim MH, Lee SJ et al (2013) Decreased metabolism in the cerebral cortex in early-stage Huntington’s disease: a possible biomarker of disease progression? J Clin Neurosci 9:21–25. https://doi.org/10.3988/jcn.2013.9.1.21 CrossRef

40.

Sritharan A, Egan GF, Johnston L et al (2010) A longitudinal diffusion tensor imaging study in symptomatic Huntington’s disease. J Neurol Neurosurg Psychiatry 81:257–262. https://doi.org/10.1136/jnnp.2007.142786 CrossRefPubMed

41.

Sturrock A, Laule C, Decolongon J et al (2010) Magnetic resonance spectroscopy biomarkers in premanifest and early Huntington disease. Neurology 75:1702–1710. https://doi.org/10.1212/WNL.0b013e3181fc27e4 CrossRefPubMedPubMedCentral

42.

Disatnik M-H, Joshi AU, Saw NL et al (2016) Potential biomarkers to follow the progression and treatment response of Huntington’s disease. J Exp Med 213:2655–2669. https://doi.org/10.1084/jem.20160776 CrossRefPubMedPubMedCentral

43.

Olsson MG, Davidsson S, Muhammad ZD et al (2012) Increased levels of hemoglobin and alpha1-microglobulin in Huntington’s disease. Front Biosci (Elite Ed) 4:950–957

44.

Wood NI, Goodman AOG, van der Burg JMM et al (2008) Increased thirst and drinking in Huntington’s disease and the R6/2 mouse. Brain Res Bull 76:70–79. https://doi.org/10.1016/j.brainresbull.2007.12.007 CrossRefPubMed

45.

Byrne LM, Wild EJ (2016) Cerebrospinal fluid biomarkers for Huntington’s disease. J Huntingt Dis 5:1–13. https://doi.org/10.3233/jhd-160196 CrossRef

46.

Chen X, Guo C, Kong J (2012) Oxidative stress in neurodegenerative diseases. Neural Regener Res 7:376–385. https://doi.org/10.3969/j.issn.1673-5374.2012.05.009 CrossRef

47.

Garrett MC, Soares-da-Silva P (1992) Increased cerebrospinal fluid dopamine and 3,4-dihydroxyphenylacetic acid levels in Huntington’s disease: evidence for an overactive dopaminergic brain transmission. J Neurochem 58:101–106. https://doi.org/10.1111/j.1471-4159.1992.tb09283.x CrossRefPubMed

48.

Kurlan R, Caine E, Rubin A et al (1988) Cerebrospinal fluid correlates of depression in Huntington’s disease. Arch Neurol 45:881–883. https://doi.org/10.1001/archneur.1988.00520320071018 CrossRefPubMed

49.

Manyam BV, Giacobini E, Colliver JA (1990) Cerebrospinal fluid acetylcholinesterase and choline measurements in Huntington’s disease. J Neurol 237:281–284. https://doi.org/10.1007/BF00314742 CrossRefPubMed

50.

Vinther-Jensen T, Simonsen AH, Budtz-Jørgensen E et al (2015) Ubiquitin: a potential cerebrospinal fluid progression marker in Huntington’s disease. Eur J Neurol 22:1378–1384. https://doi.org/10.1111/ene.12750 CrossRefPubMed

51.

Carrizzo A, Di Pardo A, Maglione V et al (2014) Nitric oxide dysregulation in platelets from patients with advanced Huntington disease. PLoS One 9:e89745. https://doi.org/10.1371/journal.pone.0089745 CrossRefPubMedPubMedCentral

52.

Byrne LM, Rodrigues FB, Blennow K et al (2017) Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington’s disease: a retrospective cohort analysis. Lancet Neurol. https://doi.org/10.1016/s1474-4422(17)30124-2 CrossRefPubMedPubMedCentral

53.

Vinther-Jensen T, Bornsen L, Budtz-Jorgensen E et al (2016) Selected CSF biomarkers indicate no evidence of early neuroinflammation in Huntington disease. Neurol Neuroimmunol Neuroinflamm 3:e287. https://doi.org/10.1212/nxi.0000000000000287 CrossRefPubMedPubMedCentral

54.

Tan Z, Dai W, van Erp TG et al (2015) Huntington’s disease cerebrospinal fluid seeds aggregation of mutant huntingtin. Mol Psychiatry 20:1286–1293. https://doi.org/10.1038/mp.2015.81 CrossRefPubMedPubMedCentral

55.

Wild EJ, Boggio R, Langbehn D et al (2015) Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington’s disease patients. J Clin Investig 125:1979–1986. https://doi.org/10.1172/JCI80743 CrossRefPubMedPubMedCentral

56.

Marcoux G, Duchez A-C, Cloutier N et al (2016) Revealing the diversity of extracellular vesicles using high-dimensional flow cytometry analyses. Sci Rep 6:35928. https://doi.org/10.1038/srep35928 CrossRefPubMedPubMedCentral

57.

van der Pol E, Boing AN, Gool EL, Nieuwland R (2016) Recent developments in the nomenclature, presence, isolation, detection and clinical impact of extracellular vesicles. J Thromb Haemost JTH 14:48–56. https://doi.org/10.1111/jth.13190 CrossRefPubMed

58.

György B, Szabó TG, Pásztói M et al (2011) Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell Mol Life Sci 68:2667–2688. https://doi.org/10.1007/s00018-011-0689-3 CrossRefPubMedPubMedCentral

59.

EL Andaloussi S, Mäger I, Breakefield XO, Wood MJA (2013) Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov 12:347–357. https://doi.org/10.1038/nrd3978 CrossRef

60.

Lötvall J, Hill AF, Hochberg F et al (2014) Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles. J Extracell Vesicles 3:26913. https://doi.org/10.3402/jev.v3.26913 CrossRefPubMed

61.

Raposo G, Stoorvogel W (2013) Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol 200:373–383. https://doi.org/10.1083/jcb.201211138 CrossRefPubMedPubMedCentral

62.

Cloutier N, Tan S, Boudreau LH et al (2013) The exposure of autoantigens by microparticles underlies the formation of potent inflammatory components: the microparticle-associated immune complexes. EMBO Mol Med 5:235–249. https://doi.org/10.1002/emmm.201201846 CrossRefPubMed

63.

Inal JM, Fairbrother U, Heugh S (2013) Microvesiculation and disease. Biochem Soc Trans 41:237–240. https://doi.org/10.1042/bst20120258 CrossRefPubMed

64.

Denis HL, Lamontagne-Proulx J, St-Amour I et al (2018) Platelet abnormalities in Huntington’s disease. J Neurol Neurosurg Psychiatry (in revision)

65.

Rousseau M, Belleannee C, Duchez A-C et al (2015) Detection and quantification of microparticles from different cellular lineages using flow cytometry. Evaluation of the impact of secreted phospholipase A2 on microparticle assessment. PLoS One 10:e0116812. https://doi.org/10.1371/journal.pone.0116812 CrossRefPubMedPubMedCentral

66.

Duchez A-C, Boudreau LH, Naika GS et al (2015) Platelet microparticles are internalized in neutrophils via the concerted activity of 12-lipoxygenase and secreted phospholipase A2-IIA. Proc Natl Acad Sci 112:E3564–E3573. https://doi.org/10.1073/pnas.1507905112 CrossRefPubMedPubMedCentral

67.

Boudreau LH, Duchez A-C, Cloutier N et al (2014) Platelets release mitochondria serving as substrate for bactericidal group IIA-secreted phospholipase A2 to promote inflammation. Blood 124:2173–2183. https://doi.org/10.1182/blood-2014-05-573543 CrossRefPubMedPubMedCentral

68.

Lamontagne-Proulx J, St-Amour I, Labib R et al (2018) Erythrocyte-derived extracellular vesicles: a novel, robust and specific biomarker that maps to Parkinson’s disease stages. Neuro Dis (Under review)

Title: Platelet-derived extracellular vesicles in Huntington’s disease
Authors: Hélèna L. Denis
Jérôme Lamontagne-Proulx
Isabelle St-Amour
Sarah L. Mason
Andreas Weiss
Sylvain Chouinard
Roger A. Barker
Eric Boilard
Francesca Cicchetti
Publication date: 01-11-2018
Publisher: Springer Berlin Heidelberg
Published in: Journal of Neurology / Issue 11/2018
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-018-9022-5

At a glance: The STEP trials

Springer Medicine

Platelet-derived extracellular vesicles in Huntington’s disease

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 11/2018

Ciclosporin and chorea: a new association?

The Brief International Cognitive Assessment in Multiple Sclerosis (BICAMS): results from the German validation study

Treatment course and outcomes after revascularization surgery for moyamoya disease in adults

Efficacy and safety of mycophenolate mofetil in progressive multiple sclerosis patients

Correlation of phenotype with genotype and protein structure in RYR1-related disorders

Ethical challenges in tracheostomy-assisted ventilation in amyotrophic lateral sclerosis